Skip to main content
. Author manuscript; available in PMC: 2019 Sep 16.
Published in final edited form as: Nat Chem Biol. 2019 Jan 28;15(3):232–240. doi: 10.1038/s41589-018-0205-2

Figure 1. Integrative analysis of epigenetic cell state and cell-selective chemosensitivity in ibrutinib-treated CLL patients.

Figure 1

Biobanked peripheral blood mononuclear cells (PBMCs) from chronic lymphocytic leukemia (CLL) patients isolated before and during ibrutinib treatment were subjected to chromatin accessibility mapping by ATAC-seq and to chemosensitivity profiling using pharmacoscopy, a single-cell automated imaging method for quantifying cell-selective drug response. To connect ibrutinib-induced changes in cell state to induced drug vulnerabilities, we mapped the ATAC-seq and pharmacoscopy data into the shared space of molecular pathways, which provide a joint basis for integrative analysis and prioritization of ibrutinib-based drug combinations for the treatment of CLL and potentially other hematopoietic malignancies.